Patients with hypertrophic obstructive cardiomyopathy after alcohol septal ablation have favorable long-term outcome irrespective of their genetic background
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F20%3A10410735" target="_blank" >RIV/00216208:11130/20:10410735 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/20:10410735
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=WKpc367Ujp" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=WKpc367Ujp</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21037/cdt.2020.01.12" target="_blank" >10.21037/cdt.2020.01.12</a>
Alternative languages
Result language
angličtina
Original language name
Patients with hypertrophic obstructive cardiomyopathy after alcohol septal ablation have favorable long-term outcome irrespective of their genetic background
Original language description
Background: The genetic background of patients with hypertrophic cardiomyopathy (HCM) treated with alcohol septal ablation (ASA) and its relationship to the outcomes are not known. We aimed to investigate whether the outcome of genotype positive (G+) patients differs from genotype negative (G-) patients treated with ASA. Methods: We included 129 HCM patients (mean age 54 +/- 13 years) treated with ASA in a tertiary cardiovascular center and performed next generation sequencing (NGS) based genomic testing. All patients were followed-up three months after the procedure and yearly thereafter. Results: A total of 30 (23%) HCM patients were G+ patients. At the 3-months follow-up, both groups of patients had similar left ventricular outflow tract PG (16.9 +/- 15.7 mmHg in G+ vs. 16.3 +/- 18.8 mmHg in G-, P=0.73) and symptoms (follow-up NYHA class 1.40 +/- 0.62 vs. 1.37 +/- 0.53, P=0.99, follow-up CCS class 0.23 +/- 0.52 vs. 0.36 +/- 0.65, P=0.36). The independent predictors of all-cause mortality were baseline interventricular septum (IVS) thickness (HR 1.12, 95% CI: 1.00-1.26, P=0.049) and age at the time of ASA (HR 1.11, 95% CI: 1.06-1.17, P<0.01). The adjusted all-cause mortality rate did not differ significantly between G+ and G- patients (P=0.52). The adjusted combined mortality event rate did not differ between both groups (P=0.78). Conclusions: Despite more severe phenotype in G+ HCM patients, ASA is an equally effective treatment for LVOTO in G+ patients as it is for treating LVOTO in G- patients. The long-term outcome after ASA is similar in G+ and G- patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
<a href="/en/project/NV15-34904A" target="_blank" >NV15-34904A: Next generation sequencing for early diagnosis and individualized therapy of hypertrophic cardiomyopathy</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cardiovascular Diagnosis and Therapy
ISSN
2223-3652
e-ISSN
—
Volume of the periodical
10
Issue of the periodical within the volume
2
Country of publishing house
CN - CHINA
Number of pages
8
Pages from-to
193-200
UT code for WoS article
000528262000010
EID of the result in the Scopus database
2-s2.0-85085984325